Blueprint Medicines revenue for the twelve months ending September 30, 2021 was $0.107B, a 86.79% decline year-over-year. Blueprint Medicines annual revenue for 2020 was $0.794B, a 1093.37% increase from 2019. Blueprint Medicines annual revenue for 2019 was $0.067B, a 49.39% increase from 2018.
11 timer siden · Blueprint Medicines’ current product revenues solely comprise sales from Ayvakit, which narrows its revenues stream. Hence, any regulatory setback for the drug could hurt the stock in the days...
1 dag siden · In the last 5 years Blueprint Medicines saw its revenue grow at 69% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance...
According to Blueprint Medicines 's latest financial reports the company's current revenue (TTM) is $0.10 B . In 2020 the company made a revenue of $0.79 B an increase over the years 2019 revenue that were of $0.06 B .The revenue is the total amount of income that a company generates by the sale of goods or services.
29.07.2021 · Pharmaceutical revenues more than doubled to $11.4 million during the quarter compared to $5.7 million in Q2 2020. Sales of Blueprint's avapritinib (Ayvakit) were $8.5 million in the second quarter compared to $5.7 million in the year-ago period, marking a 49 percent jump.
View Blueprint Medicines (www.blueprintmedicines.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar ...
Oct 28, 2021 · Blueprint recorded revenues of $745.1 million in the third quarter of 2020, including $6.1 million of net product revenues from sales of AYVAKIT, $0.2 million of net product revenues from sales of...
According to Blueprint Medicines 's latest financial reports the company's current revenue (TTM) is $0.10 B . In 2020 the company made a revenue of $0.79 B an increase over the years 2019 revenue that were of $0.06 B .The revenue is the total amount of income that a company generates by the sale of goods or services.
30.09.2021 · Blueprint recorded revenues of $745.1 million in the third quarter of 2020, including $6.1 million of net product revenues from sales of AYVAKIT, $0.2 million of net product revenues from sales of GAVRETO and $738.8 million in collaboration revenues.
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined ...
Oct 28, 2021 · Blueprint Medicines, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.19 million for the quarter ended September 2021, missing the Zacks Consensus...
Dec 10, 2021 · Blueprint Medicines's revenue was reported to be $793.74 m in FY, 2020 Summary Blueprint Medicines's current market capitalization is $5.6 b. Income Statement Annual Quarterly show all Balance Sheet Annual Quarterly show all Cash Flow Annual Quarterly show all Ratios Show all financial metrics
Blueprint Medicines revenue for the twelve months ending September 30, 2021 was $0.107B, a 86.79% decline year-over-year. Blueprint Medicines annual revenue for 2020 was $0.794B, a 1093.37% increase from 2019. Blueprint Medicines annual revenue for 2019 was $0.067B, a 49.39% increase from 2018.